AIFM3 (Apoptosis Factor Mitochondria 3) is a mitochondrial protein homologous to AIFM1 and AIFM2, involved in apoptosis and cell death pathways. AIFM3 represents a relatively uncharacterized member of the AIF family that may play distinct roles in neuronal survival and death.
| Symbol | AIFM3 |
|---|---|
| Full Name | Apoptosis-Inducing Factor Mitochondria 3 |
| Aliases | AIFL3, UNQ1947 |
| Chromosomal Location | Chr22q13.33 |
| NCBI Gene ID | 150209 |
| Protein Class | Apoptosis-inducing factor family |
AIFM3 shares structural features with other AIF family members:
AIFM3 functions as:
AIFM3 is expressed in various tissues, with notable expression in:
AIFM3 is relevant to AD through several mechanisms:
Mitochondrial Dysfunction: AD is characterized by early mitochondrial dysfunction. AIFM3, as a mitochondrial protein involved in cell death, may contribute to the progressive loss of neuronal mitochondria in AD. [4]
Oxidative Stress: AIFM3's oxidoreductase activity connects to oxidative stress in AD. The disease involves increased reactive oxygen species (ROS) production and impaired antioxidant defenses. [5]
Apoptosis vs. Necrosis: AIFM3 mediates caspase-independent cell death, which may be relevant to the necrotic-like cell death observed in AD. The balance between apoptotic and necrotic pathways influences disease progression. [6]
Amyloid-Beta Toxicity: Amyloid-beta oligomers induce mitochondrial dysfunction and cell death. AIFM3 may participate in these pathways, though its specific role in Aβ-induced toxicity remains to be characterized. [7]
Dopaminergic Neuron Vulnerability: AIFM3 may influence the selective vulnerability of dopaminergic neurons in the substantia nigra. These neurons have high metabolic demands and are particularly sensitive to mitochondrial dysfunction. [8]
Mitochondrial Complex I Deficiency: PD involves complex I deficiency. AIFM3's mitochondrial functions could interact with or be affected by complex I impairment. [9]
Cell Death Pathways: The death of dopaminergic neurons involves both apoptotic and necrotic mechanisms. AIFM3-mediated cell death pathways may contribute to this process. [10]
Motor Neuron Death: AIFM3 is expressed in motor neurons and may contribute to their degeneration in ALS. The caspase-independent cell death pathway mediated by AIFM3 could be relevant to the necrotic component of motor neuron death. [11]
Mitochondrial Dysfunction: ALS involves widespread mitochondrial dysfunction, including fragmentation, impaired function, and loss of mitochondrial DNA. AIFM3's role in mitochondrial quality control may be relevant. [12]
Excitotoxicity: Glutamate excitotoxicity is a key mechanism in ALS. Excitotoxic stress can induce mitochondrial dysfunction and cell death, potentially involving AIFM3 pathways. [13]
Ischemic Cell Death: AIFM3 may play a role in the caspase-independent cell death that occurs following cerebral ischemia. The mitochondrial permeability transition and release of mitochondrial pro-death factors contribute to infarct expansion. [14]
Oxidative Damage: Ischemia-reperfusion generates oxidative stress. AIFM3's oxidoreductase activity could be affected by or contribute to oxidative damage in stroke. [15]
Targeting AIFM3 pathways presents therapeutic opportunities:
| Protein | Interaction Type | Function |
|---|---|---|
| AIFM1 | Homolog | Apoptosis induction |
| AIFM2 | Homolog | Apoptosis regulation |
| VDAC | Pore interaction | Mitochondrial outer membrane |
| Cytochrome c | Comparison | Electron transport chain |
| Hsp90 | Chaperone interaction | Protein folding |
AIFM3 is a mitochondrial apoptosis-inducing factor with roles in caspase-independent cell death and oxidoreductase activity. Its involvement in mitochondrial dysfunction connects it to the pathogenesis of Alzheimer's disease, Parkinson's disease, ALS, and stroke. The caspase-independent cell death pathway mediated by AIFM3 represents an alternative cell death route that may be particularly relevant to the necrotic-like neuronal death observed in neurodegenerative conditions. Understanding AIFM3's role in neurodegeneration may lead to therapeutic strategies targeting mitochondrial cell death pathways.
Gereben et al. Mitochondrial targeting of AIF proteins (2008). 2008. ↩︎
Miranville et al. FAD-binding in AIF family (2004). 2004. ↩︎
Susin et al. AIF-mediated cell death (2000). 2000. ↩︎
Querfurth & LaFerla, Molecular mechanisms of AD (2010). 2010. ↩︎
O'Brien & Wong, Amyloid-beta and mitochondrial dysfunction (2011). 2011. ↩︎
Vila & Przedborski, Targeting cell death in PD (2003). 2003. ↩︎
Van Den Bosch et al. Excitotoxicity in ALS (2000). 2000. ↩︎